Abstract: A topical composition for treating fungal skin infections with associated inflammation may include making or administering to the affected skin area an antifungal and steroid, such as a corticosteroid. Certain compositions may include antifungals such as itraconazole or econazole and corticosteroids such as fluticasone, fluocinonide, or clobetasol. The antifungal and steroid may be within a cream. In one example, a commercially available econazole nitrate cream may be used in conjunction with a commercially available fluocinonide cream or commercially available clobetasol cream to treat the affected skin area.

Abstract: A thermic infusion system includes a thermal tubing system and a control system. The thermal tubing system has a tubal body with at least one tubal segment. The tubal segment includes a thermal element that may receive energy, such as electrical energy, to increase temperature within the tubal body. The control system may regulate the amount of energy received by the tubal segment using one or more sensors positioned within the tubal body.

Abstract: A topical composition that may be a lotion, gel, ointment, foam, cream, or emulsion, and that may include urea and fluocinonide. The topical composition may include between approximately 10% to approximately 25% urea by weight. The topical composition may further include between approximately 0.050% to approximately 0.075% fluocinonide by weight.

Abstract: A pistol caliber blowback operated bolt carrier group is provided with an integrated gas key.

Abstract: A method of treating or preventing one or both of a bacterial infection or fungal infection of a foot of a subject includes combining a diluent and at least one of a clindamycin solution or an erythromycin solution to form a footbath solution. The method may further include topically administering the footbath solution to the subject. Administering may include contacting with the footbath solution a skin area of the foot of the subject that is infected or suspected to be infected.

Abstract: A dry formulation may include one or more active agents including one or more anti-infective agents such as an anti-bacterial agent, anti-fungal agent, or other anti-active agent. The dry formulation may be prepared for administration by mixing the dry formulation with a diluent. In one example, the diluent is a hydrocortisone and acetic acid solution or a sodium chloride solution. The combined preparation may be administered to the ear or skin to treat or prevent an infection.

Abstract: The present application relates to compounded compositions, methods of making compounded compositions, and methods of using compounded compositions. For example, disclosed herein are compounded compositions and methods of making compounded compositions comprising one or more anti-infective agents such as mupirocin.

Abstract: A burner assembly for and method of producing ethylene having a mechanism to inject either primary fuel, staged fuel, or both by premix methods before combustion in a furnace. The burner assembly has at least one premix injection assembly for either exclusively primary fuel or exclusively staged fuel injection paired with a nozzle mix injection or injection means for primary and staged fuel both by premix methods. The primary fuel premix assembly associates with a burner tile that consists of multiple inlets and outlets connected by venturi channels to direct and combine combustion air and staged fuel coming from staged fuel orifice spuds. Primary fuel and combustion air are mixed in a premix assembly and directed inside the furnace, and above the burner tile to complete the reaction with the staged fuel and combustion air mixture in a combustion zone inside of the furnace.

Abstract: The present application relates to compounded compositions, methods of making compounded compositions, kits comprising compounded compositions, containers comprising compounded compositions, and methods of using compounded compositions. The present application also relates to anti-infective agents and methods of using anti-infective agents. For example, disclosed herein are compounded compositions comprising an anti-bacterial agent, an anti-fungal agent, and an excipient base and methods of using a compounded composition to treat or prevent a bacterial infection, a fungal infection, or both, or a suspected bacterial infection, a suspected fungal infection, or both. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Abstract: The present application relates to compounded compositions, methods of making compounded compositions, kits comprising compounded compositions, containers comprising compounded compositions, and methods of using compounded compositions. The present application also relates to anti-infective agents and methods of using anti-infective agents. For example, disclosed herein are compounded compositions comprising an anti-bacterial agent, an anti-fungal agent, and an excipient base and methods of using a compounded composition to treat or prevent a bacterial infection, a fungal infection, or both, or a suspected bacterial infection, a suspected fungal infection, or both. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Abstract: A compounded topical composition may include an antiviral component, a topical base component, and a local anesthetic component. The antiviral component may include fine powder obtained by grinding oral tablets of one or more antiviral actives. The topical component may include the local anesthetic component. The local anesthetic component may be present in an amount between about 2% and about 8% by weight of the compounded topical composition and the antiviral component may be present in an amount between 4% and 12% by weight of the compounded topical composition. The antiviral component may include acyclovir, valaciclovir, penciclovir, famciclovir, or combinations thereof, and the topical base component may be a lidocaine topical, a lidocaine and prilocaine topical, or both.

Abstract: A compounded topical composition may be compounded by combining a local anesthetic component with a topical base composition. The local anesthetic component may comprise lidocaine hydrochloride monohydrate and the topical base composition may comprise an Acyclovir 5% Ointment containing 5% acyclovir by weight and polyethylene glycol.

Abstract: A protective golf bag system includes a golf bag a removable protective cover. The cover is supported by a protector fitted into a top opening of the bag. The protector includes a divider with a plurality of arms spanning across the sides of the bag and adapted to attach to the sides. These arms form areas for inserting of a number of golf clubs. At the bottom of the bag is a plate to which is releasably anchored an extensible tube with a top portion and a bottom portion centrally positioned in the golf bag with a handle extending through a center of the divider. A button on the handle releases a connecting member at each of the top and bottom of the extensible tube that fixes the relative position of the top and bottom portions of the extensible tube.

Abstract: The present application relates to compounded compositions, methods of making compounded compositions, and methods of using compounded compositions. For example, disclosed herein are compounded compositions and methods of making compounded compositions comprising one or more anti-infective agents such as mupirocin.

Abstract: The present application relates to compounded compositions, methods of making compounded compositions, and methods of using compounded compositions. For example, disclosed herein are compounded compositions and methods of making compounded compositions comprising one or more anti-infective agents such as mupirocin and doxcycline.

Abstract: Apparatuses and methods for production of molybdenum targets, and the formed molybdenum targets, used to produce Tc-99m are described. The target includes a copper support plate having a front face and a back face. The copper support plate desirably has dimensions of thickness of about 2.8 mm, a length of about 65 mm and a width of about 30 mm; and the copper support plate desirably has either a circular or an elliptical cavity centrally formed therein by pressing molybdenum powder into the front face with a depth of about 200-400 microns. Also, the copper support plate includes cooling channels dispensed at the back face; wherein the copper support plate is water cooled by a flow of water during irradiation by a proton beam. Molybdenum powder is embedded and compressed onto the cavity of the copper support plate thereby creating a thin layer of molybdenum onto the copper support plate.

Abstract: A process for the separation of 99mTc from molybdenum targets is described. The method for separation of 99mTc isotope from molybdenum targets includes: i) providing an initial multicomponent mixture of elements, the mixture containing 99mTc; ii) dissolving the multicomponent mixture of elements with an oxidizing agent to oxidize the mixture of elements; iii) heating the mixture of elements at a temperature sufficiently high enough to sublimate a vaporized compound containing 99mTc; iv) condensing the vaporized compound containing 99mTc to form a reaction product; v) adding a base to the condensed reaction product to dissolve the 99mTc containing reaction product to form sodium pertechnetate (Na99mTcO4); and vii) purifying the crude solution of sodium pertechnetate Na99mTc04 using column chromatography to provide the 99mTc isotope as a radiochemical compound.

Abstract: The present embodiments relate to topically delivered medication (compounded) for treatment of pain, inflammation, muscle fatigue, spasms, and/or other ailments. A transdermal cream may provide the effective topical administration of multiple medications simultaneously. The transdermal cream may include a salt load of approximately 30% or greater. The transdermal cream may include a unique base composition such that the transdermal cream may be able to remain stable and avoid degradation for six months or more and capable of effective delivery of active ingredient concentrations exceeding approximately 40% or more of the total formulation weight. The active ingredients may include a nerve depressant, NSAID, muscle relaxant, opiate agonist, local anesthetic, NMDA receptor antagonist, and a tricyclic antidepressant. In one embodiment, the transdermal cream may comprise ketamine HCL, gabapentin, clonidine HCL and baclofen.

Abstract: The present embodiments relate to topically delivered compounded medications. A transdermal cream may provide the effective topical administration of multiple medications simultaneously. The transdermal cream may include low concentrations of local anesthetics, a NSAID, an anticonvulsant, and/or other active ingredients. For instance, the transdermal cream may include lidocaine, prilocaine, meloxicam, and lamotrigine and/or topiramate. Alternatively, the transdermal cream may include a lidocaine/prilocaine base cream to which is added a fine powder of one or more ground up medications to form a compounded medication. The compounded medication in powder form may be generated from grinding up tablets of NSAIDs, anticonvulsants, nerve depressants, antidepressants, muscle relaxants, NMDA receptor antagonists, opiate or opioid agonists, and/or other agents. The compounded medication in powder form may include meloxicam, lamotrigine, topiramate, and/or other active ingredients.